-
Diagnostic and surveillance testing capability for mpox in the EU/EEA, September 2024
-
View Affiliations Hide AffiliationsDaniel Palmdaniel.palm ecdc.europa.eu
-
View Citation Hide Citation
Citation style for this article: . Diagnostic and surveillance testing capability for mpox in the EU/EEA, September 2024. Euro Surveill. 2024;29(42):pii=2400632. https://doi.org/10.2807/1560-7917.ES.2024.29.42.2400632 Received: 26 Sept 2024; Accepted: 14 Oct 2024
Abstract
In response to the increasing number of mpox cases caused by monkeypox virus (MPXV) clade I in the African continent and the first reported travel-related clade Ib case of mpox in EU/EEA, the European Centre for Disease Prevention and Control surveyed national capability for detection and characterisation of MPXV in the EU/EEA. The results showed high level of capability for case confirmation by PCR, alongside molecular typing methods for identification of MPXV clades and/or clade I subclades within the EU/EEA.
Full text loading...